US Patent

US11406632 — Aripiprazole formulations having increased injection speeds

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2035-03-19 · 9y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions for the rapid intramuscular delivery of antipsychotic drugs.

USPTO Abstract

The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.

Drugs covered by this patent

Aristada (ARIPIPRAZOLE LAUROXIL) · Alkermes Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2402`	—	Aristada
`U-2402`	—	Aristada
`U-2402`	—	Aristada
`U-2402`	—	Aristada

Patent Metadata

Patent number: US11406632
Jurisdiction: US
Classification: Method of Use
Expires: 2035-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Alkermes Pharma Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.